The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas

BACKGROUND: Spinal neurofibromas (SNFs) in neurofibromatosis type 1 (NF1) can cause progressive spinal cord compression and neurological dysfunction. The MEK inhibitor selumetinib shrinks the majority of plexiform neurofibromas (PNs) in patients with NF1. We assessed the effect of selumetinib on SNF...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neurooncol Adv
Main Authors: Jackson, Sadhana, Baker, Eva H, Gross, Andrea M, Whitcomb, Patricia, Baldwin, Andrea, Derdak, Joanne, Tibery, Cecilia, Desanto, Jennifer, Carbonell, Amanda, Yohay, Kaleb, O’Sullivan, Geraldine, Chen, Alice P, Widemann, Brigitte C, Dombi, Eva
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7486535/
https://ncbi.nlm.nih.gov/pubmed/32939452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdaa095
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados